Urinary calcium response to high dose vitamin D3 with calcium supplementation in patients with multiple sclerosis

Clin Biochem. 2011 Jul;44(10-11):930-2. doi: 10.1016/j.clinbiochem.2011.04.017. Epub 2011 May 5.

Abstract

Objective: To characterize the effect of vitamin D(3) intake on urinary calcium:creatinine ratios across predefined ranges of serum 25(OH)D.

Design: Patients with multiple sclerosis (n=25) received escalating doses of vitamin D(3) (4000-40,000IU/d) with calcium (1200mg/d).

Results: Urinary calcium:creatinine was driven by increased 25(OH)D when concentrations were <75nmol/L (r=0.424, p=0.009) and >200nmol/L (r=0.281, p=0.01), but no relationship existed when 25(OH)D concentrations were 76-200nmol/L.

Conclusions: A "safe", physiological range of 25(OH)D concentrations is 75-200nmol/L.

Trial registration: ClinicalTrials.gov NCT00644904.

MeSH terms

  • Adult
  • Calcium / urine*
  • Cholecalciferol / administration & dosage*
  • Cholecalciferol / blood
  • Cholecalciferol / therapeutic use*
  • Creatinine / urine
  • Dietary Supplements*
  • Dose-Response Relationship, Drug
  • Humans
  • Multiple Sclerosis / blood
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / urine*
  • Regression Analysis

Substances

  • Cholecalciferol
  • Creatinine
  • Calcium

Associated data

  • ClinicalTrials.gov/NCT00644904